Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;28(2):202-221.
doi: 10.1016/j.cmi.2021.10.005. Epub 2021 Oct 27.

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Thibault Fiolet  1 , Yousra Kherabi  2 , Conor-James MacDonald  3 , Jade Ghosn  2 , Nathan Peiffer-Smadja  4
Affiliations
Review

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Thibault Fiolet et al. Clin Microbiol Infect. 2022 Feb.

Abstract

Background: Vaccines are critical cost-effective tools to control the coronavirus disease 2019 (COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may threaten the global impact of mass vaccination campaigns.

Aims: The objective of this study was to provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for 19 COVID-19 vaccines.

Sources: References for this review were identified through searches of PubMed, Google Scholar, BioRxiv, MedRxiv, regulatory drug agencies and pharmaceutical companies' websites up to 22nd September 2021.

Content: Overall, all COVID-19 vaccines had a high efficacy against the original strain and the variants of concern, and were well tolerated. BNT162b2, mRNA-1273 and Sputnik V after two doses had the highest efficacy (>90%) in preventing symptomatic cases in phase III trials. mRNA vaccines, AZD1222, and CoronaVac were effective in preventing symptomatic COVID-19 and severe infections against Alpha, Beta, Gamma or Delta variants. Regarding observational real-life data, full immunization with mRNA vaccines and AZD1222 seems to effectively prevent SARS-CoV-2 infection against the original strain and Alpha and Beta variants but with reduced effectiveness against the Delta strain. A decline in infection protection was observed at 6 months for BNT162b2 and AZD1222. Serious adverse event rates were rare for mRNA vaccines-anaphylaxis 2.5-4.7 cases per million doses, myocarditis 3.5 cases per million doses-and were similarly rare for all other vaccines. Prices for the different vaccines varied from $2.15 to $29.75 per dose.

Implications: All vaccines appear to be safe and effective tools to prevent severe COVID-19, hospitalization, and death against all variants of concern, but the quality of evidence greatly varies depending on the vaccines considered. Questions remain regarding a booster dose and waning immunity, the duration of immunity, and heterologous vaccination. The benefits of COVID-19 vaccination outweigh the risks, despite rare serious adverse effects.

Keywords: COVID-19; Coronavirus; Delta; Efficacy; Review; SARS-CoV-2; Seroneutralization; Vaccines; Variants.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Vaccine efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from clinical trials (in % and 95%CI) according to the number of doses. Confidence intervals are delimited by the grey rectangular area.
Fig. 2
Fig. 2
Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) asymptomatic or symptomatic infection from real-world studies (in % and 95%CI) according to the number of doses. Confidence intervals are delimited by the grey rectangular area.
Fig. 3
Fig. 3
Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hospitalization or death from real-world studies (in % and 95%CI) according to the number of doses. Confidence intervals are delimited by the grey rectangular area.
Fig. 4
Fig. 4
Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from real-world studies (in % and 95%CI) according to the number of doses. Confidence intervals are delimited by the grey rectangular area. Blue, orange, red, pale blue, green refer to Alpha, Beta, Delta, Gamma and unsequenced strains, respectively.
Fig. 5
Fig. 5
Average fold reduction in neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant versus wild type/D614G SARS-CoV-2 for each coronavirus disease 2019 (COVID-19) vaccine in 54 seroneutralization assays. The line in the middle of the box is the median. The box edges are the 25th and 75th percentiles. These boxplots included different methods assessing neutralizing antibody titres. Methods are detailed in the Supplementary Material Table S2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization Draft landscape and tracker of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand... [Internet]. [cité 30 mai 2021]
    1. Volz E., Mishra S., Chand M., Barrett J.C., Johnson R., Geidelberg L., et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021:1–17. - PubMed
    1. Coutinho R.M., Marquitti F.M.D., Ferreira L.S., Borges M.E., Silva RLP da, Canton O., et al. medRxiv; 2021. Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant. 23rd March. 2021.03.03.21252706. - PMC - PubMed
    1. Davies N.G., Jarvis C.I., Edmunds W.J., Jewell N.P., Diaz-Ordaz K., Keogh R.H. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021:1–5. - PMC - PubMed
    1. Challen R., Brooks-Pollock E., Read J.M., Dyson L., Tsaneva-Atanasova K., Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579. - PMC - PubMed

Supplementary concepts

  NODES
chat 4
COMMUNITY 1
INTERN 1
twitter 2